A PHASE 1 B/2 OPEN-LABEL STUDY with RANDOMIZATION in PHASE 2 of IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD of CARE CHEMOTHERAPY in PATIENTS with HER2/NEU OVEREXPRESSING METASTATIC or ADVANCED ADENOCARCINOMA of the STOMACH or GASTROESOPHAGEAL JUNCTION

This article has no abstract
Epistemonikos ID: 22f57cafd78af8cb5e5e2cd594a06862ad91abdb
First added on: Feb 13, 2025